Providing strong interrelations between the
arrhythmias, coronary heart failure, and thrombosis [164], assuming the venous and
arterial thrombosis as two aspects of the same disease [165,166], the BPC
157 counteracting effect might be reciprocally related.
Thus, in coronary heart failure therapy, the therapeutic
impact of BPC 157 administration may counteract the escalating
thrombosis as a shared frequent level [19,24,27,29,31,37,38,39,40].
This could be the ensuing reversal of the f |
|
|
|
